Zurayk Mira, Keung Yi-Kong, Yu David, Hu Eddie Hl
1 Department of Pharmacy, 24296 Huntington Memorial Hospital , Pasadena, USA.
2 UCLA Hematology-Oncology Clinic, Alhambra, CA, USA.
J Oncol Pharm Pract. 2019 Jan;25(1):234-238. doi: 10.1177/1078155217732141. Epub 2017 Sep 26.
5-fluorouracil and capecitabine are chemotherapeutic agents commonly used to treat solid malignancies. Increased susceptibility to 5-fluorouracil or capecitabine, caused by impaired clearance, dihydropyrimidine dehydrogenase deficiency, or other genetic mutations in the enzymes that metabolize 5-fluorouracil can lead to severe life-threatening toxicities and are typically manifested by an early onset of symptoms. We report and discuss the management and outcome of capecitabine toxicity with the recently FDA approved antidote, uridine triacetate (Vistogard), in a 57-year-old female breast cancer patient with homozygous dihydropyrimidine dehydrogenase deficiency who received treatment beyond the recommended 96 h window from the last dose of capecitabine.
5-氟尿嘧啶和卡培他滨是常用于治疗实体恶性肿瘤的化疗药物。5-氟尿嘧啶清除受损、二氢嘧啶脱氢酶缺乏或代谢5-氟尿嘧啶的其他酶发生基因突变，导致对5-氟尿嘧啶或卡培他滨的易感性增加，可引发严重的危及生命的毒性反应，其症状通常较早出现。我们报告并讨论了在一名患有纯合二氢嘧啶脱氢酶缺乏症的57岁女性乳腺癌患者中，使用最近美国食品药品监督管理局批准的解毒剂三乙酰尿苷（Vistogard）治疗卡培他滨毒性的处理方法及结果，该患者在最后一剂卡培他滨之后超过推荐的96小时窗口期仍接受了治疗。
